AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca soliris (eculizumab) — Established RoW YoY actual (%) (%)
Form 6-K / 20-F Product Sales Table
Latest, Q2 2026
-21.0%
Period ended Jun 30, 2026
Change on a year earlier
+16.0 pts
-37.0% in Q2 2025
History
20 quarters
Since Q3 2021
Sources
20
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Soliris (eculizumab) — Established RoW YoY actual (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | -21.0% | +16.0 pts | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | -19.0% | +24.0 pts | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | -20.0% | +18.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | -24.0% | +12.0 pts | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | -37.0% | -1.0 pts | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | -43.0% | -13.0 pts | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | -38.0% | -13.0 pts | Form 6-K FY2024Q4 Earnings Release ↗ |
| Q3 2024 | Sep 30, 2024 | -36.0% | -8.0 pts | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q2 2024 | Jun 30, 2024 | -36.0% | +14.0 pts | Form 6-K FY2024Q2 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | -30.0% | -12.0 pts | Form 6-K FY2024Q1 Earnings Release ↗ |
| Q4 2023 | Dec 31, 2023 | -25.0% | -7.0 pts | Form 6-K FY2023Q4 Earnings Release ↗ |
| Q3 2023 | Sep 30, 2023 | -28.0% | -23.0 pts | Form 6-K FY2023Q3 Earnings Release ↗ |
| Q2 2023 | Jun 30, 2023 | -50.0% | -113.0 pts | Form 6-K FY2023Q2 Earnings Release ↗ |
| Q1 2023 | Mar 31, 2023 | -18.0% | -22.0 pts | Form 6-K FY2023Q1 Earnings Release ↗ |
| Q4 2022 | Dec 31, 2022 | -18.0% | -25.0 pts | Form 6-K FY2022Q4 Earnings Release ↗ |
| Q3 2022 | Sep 30, 2022 | -5.0% | -14.0 pts | Form 6-K FY2022Q3 Earnings Release ↗ |
| Q2 2022 | Jun 30, 2022 | 63.0% | – | Form 6-K FY2022Q2 Earnings Release ↗ |
| Q1 2022 | Mar 31, 2022 | 4.0% | – | Form 6-K FY2022Q1 Earnings Release ↗ |
| Q4 2021 | Dec 31, 2021 | 7.0% | – | Form 6-K FY2021Q4 Earnings Release ↗ |
| Q3 2021 | Sep 30, 2021 | 9.0% | – | Form 6-K FY2021Q3 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Soliris (eculizumab) — Established RoW YoY actual (%) (%), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_soliris_erow_act_yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.